Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines

Anticancer Research

Volumn 26, Issue 3 A, 2006, Pages 2093-2099

  William Faltaos, Sara ^a   Rouillard, Dany ^b   Lechat, Philippe ^a   Bastian, Gérard ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT CURIE   (France)

Author keywords

Apoptosis; Cell cycle; Oxaliplatin

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; OXALIPLATIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; DRUG EFFECT; HUMAN; HUMAN CELL; INCUBATION TIME; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DNA, NEOPLASM; FLOW CYTOMETRY; HELA CELLS; HT29 CELLS; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 33745590136     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Faivre S, Chan D, Salinas R, Woynarowska B and Woynarowski JM: DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66: 225-237, 2003.
2. Armand JP, Boige V, Raymond E, Fizazi K, Faivre S and Ducreux M: Oxaliplatin in colorectal cancer: an overview. Semin Oncol 27: 96-104, 2000.
3. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B and Mathe G: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82: 1046-1050, 1990.
4. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K and Fojo T: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52: 1855-1865, 1996.
5. Desoize B and Madoulet C: Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 42: 317-325, 2002.
6. Misset JL, Bleiberg H, Sutherland W, Bekradda M and Cvitkovic E: Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 35: 75-93, 2000.
7. Smits VA and Medema RH: Checking out the G(2)/M transition. Biochim Biophys Acta 1519: 1-12, 2001.
8. Arnould S, Guichard S, Hennebelle I, Cassar G, Bugat R and Canal P: Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line. Biochem Pharmacol 64: 1215-1226, 2002.
9. Xu JM, Azzariti A, Severino M, Lu B, Colucci G and Paradiso A: Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin. Biochem Pharmacol 66: 551-563, 2003.
10. Eriguchi M, Nonaka Y, Yanagie H, Yoshizaki I, Takeda Y and Sekiguchi M: A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines. Biomed Pharmacother 57: 412-415, 2003.
11. Fujikane T, Shimizu T, Tsuji T, Ishida S, Ohsaki Y and Onodera S: Flow cytometric analysis of the kinetic effects of cisplatin on lung cancer cells. Cytometry 10: 788-795, 1989.
12. Simpson D, Dunn C, Curran M and Goa KL: Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs 63: 2127-2156, 2003.
13. Page JD, Husain I, Sancar A and Chaney SG: Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 29: 1016-1024, 1990.
14. Raymond E, Faivre S, Chaney S, Woynarowski J and Cvitkovic E: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1: 227-235, 2002.
15. Passalaris TM, Benanti JA, Gewin L, Kiyono T and Galloway DA: The G(2) checkpoint is maintained by redundant pathways. Mol Cell Biol 19: 5872-5881, 1999.
16. Demarcq C, Bastian G and Remvikos Y: BrdUrd/DNA flow cytometry analysis demonstrates cis-diamminedichloroplatinum (II)-induced multiple cell-cycle modifications on human lung carcinoma cells. Cytometry 13: 416-422, 1992.
17. Sorenson CM, Barry MA and Eastman A: Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82: 749-755, 1990.
18. Reardon JT, Vaisman A, Chaney SG and Sancar A: Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-acetoammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59: 3968-3971, 1999.
19. Mishima M, Samimi G, Kondo A, Lin X and Howell SB: The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 38: 1405-1412, 2002.
20. Shapiro GI and Harper JW: Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104: 1645-1653, 1999.